Protara Therapeutics is trading 9.1% down in pre-market at $3.60, with no credible company-specific announcement dated August 20, 2026, identified.
- The stock closed at $3.96 on August 19, 2026.
- Its latest reported catalyst was the August 11 second-quarter update, which included a $21.7 million net loss and missed analyst expectations; the news is too dated to clearly explain this decline.
- Biotech peers are higher, weakening a sector-based explanation.